Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

BNT327/PM8002 is designed to restore effector T-cell function by binding to PD-L1, as well as localize VEGF-A neutralization within the tumor microenvironment, therefore reversing the dampening of ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific antibody BNT327.

BioNTech SE is currently sponsoring a clinical study titled ‘A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With ...

This trial is comparing BNT327 and standard chemotherapy with atezolizumab and standard chemotherapy. It is for people having their first treatment for small cell lung cancer that has spread within ...

BioNTech SE and Bristol Myers Squibb announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific ...

Doctors are looking for ways to improve treatment for NSCLC. In this trial, they are looking at an experimental drug called BNT327. It is a new type of immunotherapy drug . It works in 2 ways. It aims ...

BNT327 is already under investigation in more than 20 clinical trials, spanning over 10 solid tumor indications. To date, more than 1,000 patients have been treated with the candidate, including in ...

Today we announce a global 50/50 strategic collaboration with BMS to jointly develop and commercialise BNT327, our anti-PDL1xVEGF antibody. Joining forces with BMS will enable us to broaden our ...

Today, we announced a global strategic partnership with BioNTech SE to co-develop and co-commercialize BNT327, an investigational, next-generation PD-L1/VEGF bispecific antibody being studied ...

BioNTech's BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date.

BNT327, BioNTech's PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...